Browsing Cancer Therapeutics by author "Minchom, Anna"
Now showing items 1-12 of 12
-
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Banerjee, S; Michalarea, V; Ang, JE; Ingles Garces, A; Biondo, A; et al. (AMER ASSOC CANCER RESEARCH, 2022-11-01)PURPOSE: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR-overexpressing tumors. PATIENTS AND METHODS: A 3+3 dose escalation ... -
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.
Tiu, C; Shinde, R; Yap, C; Rao Baikady, B; Banerji, U; et al. (ELSEVIER SCIENCE INC, 2020-07-01) -
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
Minchom, A; Thavasu, P; Ahmad, Z; Stewart, A; Georgiou, A; et al. (PUBLIC LIBRARY SCIENCE, 2017-10-05)We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected ... -
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Puglisi, M; Stewart, A; Thavasu, P; Frow, M; Carreira, S; et al. (KARGER, 2016-01-01)OBJECTIVES: We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small ... -
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Minchom, A; Aversa, C; Lopez, J (SAGE PUBLICATIONS LTD, 2018-07-13)Maintenance of genomic stability is a critical determinant of cell survival and relies on the coordinated action of the DNA damage response (DDR), which orchestrates a network of cellular processes, including DNA replication, ... -
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.
Stewart, A; Coker, EA; Pölsterl, S; Georgiou, A; Minchom, AR; et al. (AMER ASSOC CANCER RESEARCH, 2019-08-01)It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic ... -
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
Coker, EA; Stewart, A; Ozer, B; Minchom, A; Pickard, L; et al. (AMER ASSOC CANCER RESEARCH, 2022-06-01)We hypothesize that the study of acute protein perturbation in signal transduction by targeted anticancer drugs can predict drug sensitivity of these agents used as single agents and rational combination therapy. We assayed ... -
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo, C; Chénard-Poirier, M; Roda, D; de Miguel, M; Harris, SJ; et al. (ELSEVIER SCIENCE INC, 2020-11-01)BACKGROUND: CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by ... -
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom, A; Yuan, W; Crespo, M; Gurel, B; Figueiredo, I; et al. (BMJ PUBLISHING GROUP, 2020-03-01)BACKGROUND: This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. CASE PRESENTATION: A 77-year-old woman with advanced epithelioid ... -
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
Moss, CA; Cojocaru, E; Hanwell, J; Ward, S; Xu, W; et al. (ELSEVIER SCI LTD, 2019-06-01)BACKGROUND: Molecular aberrations in cancer may represent therapeutic targets, and, if arising from the germline, may impact further cancer risk management in patients and their blood relatives. Annually, 600-700 patients ... -
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
Collins, DC; Sundar, R; Constantinidou, A; Dolling, D; Yap, TA; et al. (BMC, 2020-12-09)BACKGROUND: Malignant pleural mesothelioma (MPM) is traditionally characterized by local destructive spread of the pleura and surrounding tissues. Patient outcomes in MPM with distant metastatic dissemination are lacking. ... -
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.
Terbuch, A; Tiu, C; Candilejo, IM; Scaranti, M; Curcean, A; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-15)PURPOSE: Drug-induced interstitial lung disease (DILD) is a rare, but potentially fatal toxicity. Clinical and radiological features of DILD in the early experimental setting are poorly described. PATIENTS AND METHODS: A ...